Experience

Davis Polk advised Ultra Clean Holdings, Inc. on its SEC-registered follow-on public offering of 4,761,905 shares of common stock for an aggregate price to the public of approximately $100…

Davis Polk advised Natura Cosméticos S.A. in connection with its $750 million offering of 5.375% senior notes due 2023, which were issued pursuant to Rule 144A and Regulation S under the…

Davis Polk advised Grupo Financiero Santander México, S.A.B. de C.V. (“Grupo Financiero Santander México”) and Banco Santander (México), S.A., Institución de Banca Múltiple, Grupo…

Davis Polk advised Auris Medical Holding AG on its registered direct offering of 12,499,999 of its common shares and concurrent private placement of warrants to purchase up to 7,499,999 of…

Davis Polk advised the joint book-running managers in connection with the $133.7 million initial public offering of common stock of Solid Biosciences Inc. The common stock is listed on the…

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the SEC-registered offering of 13,333,333 shares of common stock of ConforMis,…

Davis Polk advised the joint book-running managers in connection with a $115 million SEC-registered offering of 5,897,435 shares of common stock of Five Prime Therapeutics, Inc. The…

Davis Polk advised the representatives of the underwriters in connection with Gates Industrial Corporation plc’s initial public offering of 38,500,000 ordinary shares, at $19.00 per share,…

Davis Polk advised the joint book-running managers in connection with a $124.5 million SEC-registered follow-on offering of 3,000,000 shares of common stock of Adamas Pharmaceuticals, Inc…

Davis Polk advised the representatives of the several underwriters, in an SEC-registered offering by Ensco plc of $1 billion aggregate principal amount of its 7.75% senior notes due…